Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen Inc. (BIIB) – Form 4 insider transaction
Independent director Dr. Lloyd Minor reported the acquisition of 2,370 shares of Biogen common stock on 17-Jun-2025. The transaction code “A” indicates that the shares were awarded rather than purchased on the open market; the reported price is $0, consistent with a restricted stock or director equity grant. Following the grant, Dr. Minor’s total direct ownership stands at 2,370 shares. No derivative securities were involved, and there were no dispositions.
The filing is routine director compensation disclosure and does not reveal any change in strategy, operations, or financial condition. However, fresh equity ownership marginally strengthens alignment between the director and shareholder interests.
Form 4 overview: On 06/17/2025, Biogen Inc. (BIIB) director Monish D. Patolawala reported the acquisition of 2,370 shares of common stock at a stated price of $0.00, suggesting a share grant or similar equity award. Following the transaction, Mr. Patolawala now beneficially owns 3,710 shares, held directly.
The filing contains no derivative security activity, sales, or monetary purchase and therefore does not indicate cash outlay or immediate market transactions. While the increase in personal holdings modestly aligns the director’s interests with shareholders, the size of the transaction is relatively small against Biogen’s roughly $33 billion market capitalization, implying limited near-term market impact.
Biogen Inc. (BIIB) – Form 4 insider filing
Director Jesus B. Mantas reported one transaction dated 06/17/2025. The filing shows an "A" transaction code (acquisition) for 2,370 shares of Biogen common stock at a stated price of $0.00, indicating a stock award or grant. After this transaction, the director’s direct beneficial ownership increases to 9,758 shares. No derivative security transactions were reported, and there are no sales or dispositions disclosed in the filing.
The form was signed by an attorney-in-fact on 06/18/2025. No other insiders or joint filers are involved, and there is no indication that the reporting person is no longer subject to Section 16.
Biogen Inc. (BIIB) has filed a Form 4 indicating that director William A. Hawkins acquired 2,370 shares of the company’s common stock on 06/17/2025. The transaction is coded “A” (acquisition) and carries a reported price of $0, suggesting the shares were granted rather than purchased on the open market. Following the transaction, Hawkins’ direct beneficial ownership stands at 8,860 shares.
The filing confirms Hawkins’ role as a director and notes the document was signed on 06/18/2025 by attorney-in-fact Wendell Taylor. No derivative security activity or additional transactions were reported.
Biogen Director Maria C. Freire reported the acquisition of 2,370 shares of Common Stock on June 17, 2025. The shares were acquired at $0 per share, suggesting this was likely a stock grant as part of director compensation.
Following this transaction, Freire now beneficially owns a total of 6,815 shares directly. The filing indicates this was a direct ownership transaction, with no indirect holdings reported. The Form 4 was signed by Wendell Taylor as attorney-in-fact for Dr. Freire on June 18, 2025.
This insider transaction represents a notable increase in Freire's equity stake in Biogen, demonstrating continued alignment between director and shareholder interests. No derivative securities were involved in this transaction.
Biogen Inc. (BIIB) – Form 4 insider transaction
Director Eric K. Rowinsky reported the acquisition of 2,370 shares of Biogen common stock on 06/17/2025. The filing lists the transaction code “A,” indicating the shares were acquired rather than sold; the stated price is $0.00, suggesting a board-related equity grant or similar stock-based award. Following the transaction, Rowinsky’s direct beneficial ownership increased to 24,339 shares, up from 21,969 shares—an increase of roughly 11%.
No derivative securities were reported, and there were no dispositions. The filing was signed on 06/18/2025 by an attorney-in-fact.
From an investment perspective, the event is routine and low-impact: it reflects standard director compensation and modestly tightens alignment between the board member and shareholders without affecting Biogen’s capital structure or cash flows.
SEC Form 4 filed on 06/18/2025 reveals that Biogen Inc. (BIIB) director Susan K. Langer acquired 2,370 shares of common stock on 06/17/2025. The transaction is coded “A,” indicating an acquisition, and carries a stated price of $0 per share, characteristic of a director equity grant rather than an open-market purchase. Following the award, Langer’s direct beneficial ownership rises to roughly 5,129 shares. No derivative security activity or additional transactions were reported. The filing was signed by attorney-in-fact Wendell Taylor on behalf of the director. No other material changes or footnotes accompany the filing.
Biogen Inc. (BIIB) Director Caroline Dorsa reported acquiring 3,160 shares of Common Stock on June 17, 2025. The shares were awarded at a price of $0, suggesting this was a stock grant as part of director compensation.
Following this transaction, Dorsa now beneficially owns a total of 31,002 shares directly. The filing indicates this was a straightforward acquisition with no derivative securities involved in the transaction.
The Form 4 was signed by Wendell Taylor as attorney-in-fact for Caroline Dorsa on June 18, 2025, within the required reporting timeline. This transaction appears to be part of regular director compensation practices rather than open market trading activity.